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Background: This study examined colonisation with and characteristics of antimicrobial-resistant organisms among
residents of a long-term care facility (LTCF) over one year, including strain persistence and molecular diversity
among isolates of extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae.
Methods: Sixty-four residents of a LTCF were recruited (51 at baseline, 13 during the year). Data on dependency
levels, hospitalisations, and antimicrobial prescribing were collected. Nasal and rectal swabs and catheter urine
specimens were examined quarterly, using chromogenic agars, for ESBL-producing Enterobacteriaceae,
carbapenemase-producing Enterobacteriaceae (CPE), vancomycin-resistant enterococci (VRE), and meticillin-resistant
S. aureus (MRSA). All ESBL-producing E. coli (ESBL-EC) were characterised by pulsed-field gel electrophoresis (PFGE)
and PCR to assess for sequence type (ST) ST131, its resistance-associated H30 and H30-Rx subclones, and blaCTX-M,
blaTEM, blaSHV, and blaOXA-1.
Results: The overall number of residents colonised, by organism, was as follows: ESBL-EC, 35 (55%); MRSA, 17 (27%);
ESBL-producing K. pneumoniae (ESBL-KP), 5 (8%); VRE, 2 (3%) and CPE, 0 (0%). All 98 ESBL-EC isolates were H30-Rx ST131,
with blaCTX-M-group 1. By PFGE, a group of 91 ESBL-EC (from 33 participants) had≥ 85% similar profiles and resembled UK
epidemic strain A/ international pulsotype PFGE812. Sequential ESBL-EC from individual residents were closely related. Six
ESBL-KP isolates, from five participants, had blaCTX-M-group 1 and by PFGE were closely related. Colonisation with ESBL and
MRSA was associated with location within the LTCF and previous exposure to antimicrobials.
Conclusions: Among LTCF residents, colonisation with ESBL-EC and MRSA was common. All ESBL-EC were H30-Rx ST131,
consistent with clonal dissemination.
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Antimicrobial resistance has been identified as a key
public health challenge [1]. Amongst the major acquired
antimicrobial-resistant organisms (AROs) are extended-
spectrum beta-lactamase (ESBL)-producing Enterobacte-
riaceae, carbapenemase-producing Enterobacteriaceae
(CPE), vancomycin-resistant enterococci (VRE), and
meticillin-resistant Staphylococcus aureus (MRSA).
ESBL-producing E. coli (ESBL-EC) have become in-
creasingly common throughout the world. In Ireland,
ESBL-EC represented 10% of all E. coli bloodstream in-
fections in 2013, compared with 3% in 2006 [2]. Spread
of CTX-M beta-lactamases is linked with specific epi-
demic clonal groups such as E. coli sequence type ST131
(typically of serotype O25b:H4). Although ST131 has
been identified from as early as 1967, ST131 isolates
containing ESBLs, predominantly CTX-M-15, emerged
mainly in the 2000s [3,4]. There is significant genomic
diversity within ST131, with over 170 distinct PFGE pat-
terns/pulsotypes (>94% similar XbaI PFGE profiles)
recognised, some of which are associated with particular
sources and antimicrobial resistance patterns [3].
The H30 ST131 subclone, so named for its carriage of
allele 30 of fimH (type 1 fimbrial adhesin gene), report-
edly expanded and disseminated rapidly after 2000 to
become the most common subclone among clinical E.
coli isolates globally [5,6]. H30 is closely associated with
fluoroquinolone resistance [5,6]. ESBL-EC, most of
which carry blaCTX-M-15, belong mainly to a subset
within H30 known as H30-Rx, which is strongly associ-
ated with sepsis [5,7].
Analogous to ST131 among ESBL-EC, several widely dis-
seminated clonal groups of ESBL-producing K. pneumoniae
(ESBL-KP) have also been identified, including K.
pneumoniae ST11, ST15, ST16, ST23, and ST48
[8-12]. Recently, emerging carbapenem resistance has
been reported in both E. coli and K. pneumoniae, further
limiting options for antimicrobial therapy for these
organisms [13,14].
Since the first Klebsiella pneumoniae carbapenemase
(KPC)-producers were reported in Ireland in 2009, and
the first KPC-producing E. coli in 2011, the numbers of
CPE detected are increasing [15,16]. Likewise, VRE has
caused an increasing proportion of all enterococcus
bloodstream infections in Ireland in recent years [17]. By
contrast with the above antimicrobial-resistant organ-
isms, MRSA as a proportion of all S. aureus bloodstream
infection has declined markedly, although strains isolated
remain predominantly the hospital-associated strains that
have been prevalent for decades [17,18].
There is increasing evidence that long-term care facil-
ities (LTCFs) are important reservoirs for AROs, includ-
ing reports of widespread colonisation and outbreaks
[19-23]. This phenomenon is likely to increase inimportance, since the proportion of the European Union
population aged ≥ 65 years is now 16% and will increase
to 29.3% (152.6 million) by 2060 [24]. This is likely to
further increase the population residing in LTCFs, cur-
rently at 19,800 in Ireland (2012) and approximately 3.7
million in the EU (2010) [24,25].
Risk factors for acquisition of AROs such as old age,
urinary catheterisation, antimicrobial consumption, and
hospitalisation are common among residents of LTCFs
[26-30]. Although there are a number of studies of
prevalence of AROs in LTCFs, there are few longitudinal
studies regarding the stability of colonisation over time,
especially in relation to molecular characteristics of colo-
nising organisms [31]. The aims of this study were: (i) to
determine the baseline prevalence of colonisation; (ii) to
monitor residents’ colonisation status at quarterly intervals
over one year; (iii) to identify risk factors for colonisation;
(iv) to characterise the antimicrobial susceptibility of the




The study was based in a newly built 100-bed LTCF that
had 88 residents at the start of the study. There are four
discrete care areas, with residents grouped by depend-
ency level. Based on the Barthel Index, residents in care
areas 1 and 2 are generally highly dependent for assist-
ance for the 10 activities for daily living care (daily care),
whereas those in care areas 3 and 4 require only occa-
sional assistance with daily living (intermittent care). To
simplify the models for statistical analysis, the four care
areas were collapsed into two groups. Each of the four
care areas has 21 single and two double en-suite rooms,
a dining area, and a day room. There are two lifts and
two sets of stairs.
Ethical approval
Ethical approval was granted by the Galway University
Hospital Ethics Committee. Written consent was ob-
tained at the outset and participants could withdraw
from the study at any time.
Design and data collection
The study period was July 2012-August 2013. For each
participating resident, data collected included gender,
age on admission, date of admission, from where the
resident was admitted, presence of an indwelling urinary
catheter, systemic antimicrobial treatment, and hospital-
isation in the previous 12 months, and previous ESBL,
CPE, VRE, and MRSA result recorded before study com-
mencement. At each quarterly interval additional data
were recorded, including recent antimicrobial treatment
in the LTCF, number of residents in the same room,
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score (dependency Index), and location within the LTCF.
However, data regarding antimicrobial treatment received
during intercurrent hospitalisation were not accessible.
Antimicrobials were classified as: (1) narrow spectrum
beta-lactams, (2) broad spectrum beta-lactams, (3) quin-
olone/fluoroquinolones, (4) nitroimidazole, (5) nitrofuran-
toin, and (6) others. An antimicrobial day was defined as
any day on which a resident received an antimicrobial.Clinical sample collection
At quarterly intervals nasal and rectal swabs were col-
lected from each participating resident, and urine sam-
ples were obtained from catheterised participants.Laboratory detection
Rectal swabs were cultured on chromogenic agar for
detection of ESBL-producing Enterobacteriaceae and
vancomycin resistant enterococcci (ID™ ESBL agar and
chrom ID™ VRE agar (bioMérieux, Marcy l’Etoile,
France)). The Centers for Disease Control and Preven-
tion (CDC) method was applied to detect CPE [32,33].
Nasal swabs were cultured on chrom ID™ MRSA agar
(bioMérieux, Marcy l’Etoile, France). In each case sus-
pect colonies were subcultured for identification by
standard methods and susceptibility testing was per-
formed in accordance with EUCAST disk diffusion
methods [34].Molecular analysis
All ESBL-EC and ESBL-KP isolates were tested by PCR
for blaCTX-M, blaTEM, blaSHV, and blaOXA-1 as described
previously [35,36]. E. coli were tested for ST131-specific
single-nucleotide polymorphisms (SNPs) in pabB by
PCR and, for isolates testing positive, additional SNP-
based PCR reactions were performed to identify the H30
and H30-Rx subclones [5,37,38]. XbaI pulsed-field gel
electrophoresis (PFGE) analysis was done according to
the Pulse-Net protocol [39]. PFGE profiles were analysed
using the Dice coefficient with clustering by the un-
weighted pair group method with arithmetic averaging
(UPGMA). For reference, E. coli ST131 isolates repre-
senting UK Strains A, C, and D, and international
pulsotypes PFGE788, PFGE797, PFGE800, PFGE806,
PFGE812, PFGE837, PFGE842, PFGE903, PFGE905,
PFGE906, PFGE945, PFGE968, PFGE987, and PFGE1140
were included in the E. coli PFGE analysis [3,40]. Simi-
larly, representative K. pneumoniae isolates for STs
ST14, ST15, ST16, ST23, ST35, ST37, ST45, ST48,
ST101, ST147, ST161, ST258, ST280, ST307, ST392,
ST429, and ST1236 were included in the K. pneumoniae
PFGE analysis.Environmental sampling
In August 2013, after commencement of the longitu-
dinal study, environmental sampling was performed to
detect ESBL-EC, ESBL-KP, VRE, and MRSA. Samples
were taken from five en-suite bedrooms and two
shared toilet facilities. The criteria for the selection of
the five bedrooms was based on the selection of bed-
rooms of residents who tested positive for carriage of
ESBL-EC, VRE and MRSA (n = 1), ESBL-EC and
ESBL-KP (n = 1), ESBL-EC only (n = 1), ESBL-KP only
(n = 1), and one occupant who did not have detectable
colonisation with any of the target organisms (n = 1).
The five bedrooms selected were based in two care
areas and one common bathroom was selected from
each of these two care areas. Eleven sites in each bed-
room and seven sites in each shared toilet facility were
tested. Selected sites included door handles entering
and exiting areas, floor surface at base of toilet, han-
dles beside showers, toilet flushers, toilet seats, tap
handles, railings beside toilets, bed-frames, bed-side
lockers, and on-call buttons.
Sites were swabbed using Copan ESwabs (BS ISO
18593:2004) and inoculated into peptone water over-
night. Ten microlitres of peptone water was plated onto
chromID™ MRSA, chromID™ESBL agar and chro-
mID™VRE (bioMerieux) for detection of MRSA, ESBL,
and VRE respectively. Identification of suspect isolates
was by standard methods and susceptibility testing was
interpreted by EUCAST methods and criteria [34].Statistical analysis
For ESBL and MRSA colonisation univariate compari-
sons were made to identify associations with patient
characteristics.
Generalised Estimating Equations (GEE) models with
an exchangeable correlation structure were used to in-
vestigate the longitudinal effects taking dependency be-
tween repeated measurements in the same individual
into account (repeated individual measures at 0, 3, 6, 9
and 12 months). A forward selection procedure was used
to estimate the relation between ESBL/MRSA colonization
and specific or general antimicrobial use. Potential con-
founding effects included in the models were previous col-
onisation, care area, hospitalisation, age, gender and other
patient characteristics. Age and gender were kept in the
final model, however other variables were only included if
found to be a confounder. Interaction terms were checked
but omitted if not significant. P-values <0.05 were con-
sidered statistically significant. Results are presented as
adjusted odds ratios (OR) (adjusted for potential con-
founders) with corresponding 95% confidence intervals
(CI). Analyses were done using SPSS for Windows ver-
sion 20 and STATA/IC version 13.0.
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Participating residents
Sixty-four LTCF residents agreed to participate in this
study, including 51 (58% of 88 initial residents) at base-
line and 13 (45% of 29 subsequently admitted residents)
later in the year. The 51 baseline enrolees had a 76-
month median prior length of stay in the LTCF. Thirty-
four of these participants remained in the study for the
entire study year whereas 17 withdrew early (15 due to
ill health or death and 2 refused repeated sampling);
however, all but 3 of the 17 had at least two rectal and
nasal samples taken prior to withdrawal. All 13 newly
admitted residents who were enrolled partway through
the study year were followed until the end of the study.
Of these participants, 11 entered the LTCF from
hospital, one from home, and one from another LTCF.
Key participant characteristics are summarised in Table 1.
During the study period, 10 baseline participants and
one new participant were hospitalised (for from 2 to 40
hospital days each). Additionally, 28 baseline and 5 new
participants received antimicrobials while in the LTCF
(for from 3 to 203 antimicrobial days each).
Detection and characterisation of ESBL-producing E. coli
As summarised in Table 2, ESBL-EC were detected in 35
(55%) of the 64 participants, including 28 (80%) by the
first rectal swab, and seven (20%) by subsequent rectal
swabs. For the 24 positive ESBL-EC participants with atTable 1 Demographics and clinical details of the 64
long-term care facility participants
Factor Description N % of 64
Gender Male 34 53
Female 30 47
Admission group Hospital 6 9
Long-term care facility 19 30
Home 39 61
Diabetic Yes 16 25
Care area 1&2 30 47
3&4 34 53
Urinary catheter Yes 9 14
Wound/ulcer Yes 8 13
Antimicrobialsa In year previous 31 48
Antimicrobialsb During study 33 52
Hospitalisationc In year previous 11 17
Hospitalisationd During study 37 58
Mean (SD) Min-max Median
Age 80 (10.52) 37-98 80
Initial barthel index 33 (33.17) 0-100 17.5
a-dDetails were only accessible for participants in the long-term care facility
during the time period, therefore no information on prior hospitalisation and
antimicrobial usage was included for new admissions.least two available follow-up (3 or more total) swabs,
75% remained positive for ≥ 6 months and 42% remained
positive for ≥ 1 year. Most (71%) of the ESBL-EC-
colonised participants were from (high-dependency) care
areas 1 and 2. Approximately half (51%) of baseline par-
ticipants remained un-colonised throughout, and when
new admissions were taken into account, 45% of resi-
dents were not colonised.
The 98 ESBL-EC isolates were recovered from rectal
(n = 95) and urine samples (n = 3) and were uniformly
resistant to ciprofloxacin, and susceptible to cefoxi-
tin, ertapenem, meropenem, and gentamicin. They
all belonged to the H30-Rx ST131 subclone and carried
blaCTX-M group 1. Eighty-five (87%) also contained blaOXA-1,
whereas none contained blaTEM or blaSHV (Table 3).
All 85 blaOXA-1-positive isolates were co-amoxiclav-
resistant, whereas all blaOXA-1 negative isolates were
co-amoxiclav-susceptible.
In a PFGE dendrogram that included each colonised
resident’s first ESBL-EC isolate (n = 35) and selected ref-
erence isolates, the study isolates clustered with the
three UK and international reference ST131 strains at
72% profile similarity (Figure 1). The H30-Rx ST131 iso-
lates were divided into two clusters (clusters A and B),
each with ≥ 85% profile similarity. Cluster A comprised
91 isolates from 33 participants and included reference
isolates for UK strain A and international PFGE812.
Cluster B comprised six isolates from two participants
and UK strain D.
Detection and characterisation of ESBL- producing K.
pneumoniae
At baseline, none of the participants tested positive for
ESBL-KP; however, five subsequently tested positive, in-
cluding three from a high dependency area and two
from a low dependency area. The positive tests occurred
at study months 3, 6, 9, and 12, in 2, 0, 2, and 2 partici-
pants, respectively (Table 2). Of the five ESBL-KP-
colonised individuals, four were also colonised with
ESBL-EC, therefore in total there were 36 residents colo-
nised with ESBL-producing Enterobacteriaceae. None of
the five ESBL-KP-colonised individuals had previously
been identified as an ESBL carrier and only one had
been hospitalised or received antimicrobials within three
months of first being detected positive. That individual
was newly admitted to the LTCF in May 2013 with
ESBL-KP already present in the LTCF. All six ESBL-KP
isolates were resistant to ciprofloxacin and gentamicin,
and susceptible to piperacillin/tazobactam, cefoxitin, erta-
penem, and meropenem. The six isolates were 91% similar
by PFGE (Figure 2) and positive for blaCTX-M group 1,
blaSHV, and blaOXA-1 (Table 3). The two isolates collected
in October 2012 from different participants were indis-
tinguishable by PFGE. The four subsequent isolates,
Table 2 Results for all participants tested from 0 to 12 months for colonisation with the targeted antimicrobial
resistant organisms
Proportion colonised (%)
Resistance phenotype July 2012f October 2012f January 2013f May 2013f August 2013f Any time point
ESBL-ECa 20/51 (39%) 21/51 (41%)7 14/50 (28%) 21/49 (43%)7 19/45 (42%)7 35/64 (55%)
ESBL-KPb 0/51 (0%) 2/51 (4%) 0/50 (0%) 2/49 (4%) 2/45 (4%) 5/64 (8%)
CPEc 0/51 (0%) 0/51 (0%) 0/50 (0%) 0/49 (0%) 0/45 (0%) 0/64 0%)
VREd 0/51 (0%) 0/51 (0%) 1/50 (2%) 1/49 (2%) 1/45 (2%) 2/64 (3%)
MRSAe 8/51 (16%) 9/51 (18%) 7/50 (14%) 7/49 (14%) 4/45 (9%) 17/64 (27%)
Any of above 24/51 (47%) 25/51 (49%) 17/50 (34%) 23/49 (47%) 20/45 (44%) 39/64 (61%)
aESBL-EC; Extended-spectrum beta-lactamase producing-Escherichia coli.
bESBL-KP; Extended-spectrum beta-lactamase-producing-Klebsiella pneumoniae.
cCPE; Carbapenemase-producing Enterobacteriaceae.
dVRE; Vancomycin-resistant enterococci.
eMRSA; Meticillin-resistant Staphylococcus aureus.
fNumber of participants tested at each interval varied, accounting for participants who died, withdrew from the study, or newly joined the study.
gOne resident had an ESBL-EC positive urine and rectal culture.
Ludden et al. BMC Infectious Diseases  (2015) 15:168 Page 5 of 12collected from three participants in May and August 2013
(one patient was positive in both May and August), were
indistinguishable from one another by PFGE but differed
from the previous isolates by 3 bands (Figure 2). In com-
parison with a collection of ESBL-KP isolates from other
regions of Ireland (unpublished data, D. Morris) the
present isolates exhibited 86% PFGE profile similarity to
reference isolates from K. pneumoniae clonal complex
(CC) CC43 (i.e., ST48 and ST123).
Detection and characterisation of CPE, VRE, and MRSA
Carbapenemase-producing Enterobacteriaceae were not
detected and vancomycin-resistant E. faecium were de-
tected in only two participants. MRSA were detected in
17 (27%) of the 64 participants, including 11 (65%) by
the first nasal swab, and six (35%) by subsequent nasal
swabs. The 17 MRSA colonised residents comprised 13
baseline participants; 8 of 13 positive on the first round
of screening, and four new participants (Table 2). Of the
17 (27% of 64) total participants colonised with MRSATable 3 Correlation of pulsed-field gel electrophoresis (PFGE)
among 124 antimicrobial-resistant Escherichia coli and Klebsie
residents
Organism PFGE cluster No. of isolates bla genes, no. of is
blaCTX-M-group-1
b
E. coli EcAc 91 91
E. coli EcA1d 2 1
E. coli EcBe 6 6
K. pneumoniae KpAf 6 6
aST = sequence type (from multilocus sequence typing). Inferred from PCR-based as
type (ST) for K. pneumoniae strains.
bAlthough other blaCTX-M genes were tested for including blaCTX-M-group-2, blaCTX-M-gr
than blaCTX-M-group-1.
cEcA = ESBL-EC (n = 91) represented in PFGE Cluster A and similar to representative
dEcA1 = ESBL-EC (n = 1) demonstrating 83% similarity to strains in PFGE Cluster A.
eEcB = ESBL-EC (n = 6) represented in PFGE Cluster B.
fKpA = ESBL-KP PFGE cluster similar to ST1236.
gST1236 is a single-locus variant of ST48; both are part of clonal complex 43.at some point, six (35%) were positive for MRSA on two
or more subsequent tests after their first positive test.
Five (29%) of 17 MRSA-positive participants had been
recognised as such prior to their first positive study test
based on clinical samples from wound (n = 2) or nasal/
body swabs (n = 3).
Co-colonisation with multiple antimicrobial-resistant
organisms
Co-colonisation with different AROs was common, with
14/36 (39%) ESBL-producing Enterobacteriaceae-positive
participants also positive for MRSA, compared with 3/28
(11%) non-ESBL-colonised participants (P = 0.008). The
two VRE-colonised participants were also colonised with
ESBL-EC and MRSA. Of the 14 participants’ positive for
both ESBL-producing Enterobacteriaceae and for MRSA,
10 were high dependency with a Barthel Index score of 25
or less indicating immobility and no level of ability/requir-
ing major help to perform activities of daily living. The
remaining four participants had Barthel Index Scoresclusters with bla type, sequence type, and subclone
lla pneumoniae isolates from long-term care facility
olates STa and subclone (no. of isolates)
blaTEM blaSHV blaOXA-1
0 0 79 ST131 H30-Rx(91)
0 0 0 ST131 H30-Rx (1)
0 0 6 ST131 H30-Rx (6)
0 6 6 ST1236/ST48 (6)g
says for E. coli and by PFGE similarity to reference strains of known sequence
oup-8, blaCTX-M-group-9, and blaCTX-M-group-25, none were detected other
of UK Strain A and international PFGE812.
Figure 1 (See legend on next page.)
Ludden et al. BMC Infectious Diseases  (2015) 15:168 Page 6 of 12
(See figure on previous page.)
Figure 1 Dendrogram of XbaI pulsed-field gel electrophoresis (PFGE) profiles for Escherichia coli isolates. One representative of each
PFGE type per subject was included in the dendrogram, which includes extended-spectrum β-lactamase-producing E. coli (ESBL-EC) (n = 35)
isolates, plus reference strains representing UK Strains A and D, and international pulsotype labelled USA Control 812. Reference strains with ≥ 85%
profile similarity to study isolates are shown. The dendrogram was generated using the unweighted pair group method with arithmetic mean
(UPGMA) algorithm based on Dice similarity coefficients. Two PFGE clusters (A and B) were defined based on ≥ 85% profile similarity. Isolates
labelled “ESBL E. coli” represent ESBL-EC.
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to perform all activity of daily living independence from
any help.
Environmental sampling
Four bedrooms and two common bathrooms were sam-
pled based on the occupants’ colonisation status and care
area; one with ESBL-EC, VRE and MRSA, one with ESBL-
EC and ESBL-KP, one with ESBL-EC only, one with ESBL-
KP only, and one occupant did not have detectable
colonisation with any of the target organisms. MRSA was
recovered from 12/69 (17%) environmental swabs, and
from 5/7 (71%) rooms sampled. The only two rooms in
which MRSA was not detected included one shared toilet
facility and the bedroom of a resident in whom colonisa-
tion with ESBL-producing Enterobacteriaceae, VRE, and
MRSA was not detected. Among the five MRSA-positive
rooms, MRSA was recovered at least once from each of
the 11 types of surfaces sampled, except for tap handles,
railing beside the toilet, and the on-call button. ESBL-
producing Enterobacteriaceae and VRE were not detected
in environmental cultures.
Longitudinal analysis of ESBL and MRSA colonisation
For ESBL-producing Enterobacteriaceae, receipt of any
antimicrobial in the previous 3 months more than dou-
bled the odds of colonisation (odds ratio 2.4 (1.5-3.8)).Figure 2 Dendrogram of XbaI pulsed-field gel electrophoresis (PFGE)
six ESBL-producing Klebsiella pneumoniae isolates, from 5 participants from
the unweighted pair group method with arithmetic mean (UPGMA) algoritIn a more detailed model that included antimicrobial class,
use in the previous three months of broad-spectrum beta-
lactam antimicrobials (OR 2.1 (1.2-3.4) or nitrofurantoin
(OR 3.5 (1.1-11.3) was independently associated with
ESBL colonisation. Care area was also an independent risk
factor, with participants in (high-dependency) areas 1 and
2 having a nearly four-fold increased odds of ESBL colon-
isation (OR 3.9 (1.6-9.7).
For MRSA, receipt of any antimicrobials in the pre-
vious three months conferred a 3.1-fold (1.1-9.1)
higher odds of testing MRSA-positive. Care area was
also independently associated with MRSA colonisation,
with participants in care areas 1 and 2 having a 6.9-fold
(1.6-29.3) higher odds of testing MRSA-positive. Add-
itional independent correlates of MRSA colonization in-
cluded previous MRSA positivity (OR 17.7 (3.8-83.1)) and
age (OR 1.12 (1.0-1.2)). No specific antimicrobial class was
independently associated with MRSA colonisation.
Discussion and conclusions
This is the first study to our knowledge that provides
longitudinal data on colonisation with AROs and risk
factors for colonisation in a LTCF. The need for such
studies has been recognised as urgent in a recent editor-
ial on E. coli ST131 [31]. Our study yielded nine key
findings. First, ESBL-EC were detected in more than
50% of participants of the study LTCF. Second, MRSAprofiles for Klebsiella pneumoniae isolates. PFGE dendrogram of the
October 2012 – August 2013. The dendrogram was generated using
hm based on Dice similarity coefficients. All profiles are ≥ 91% similar.
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colonisation of ESBL-EC and MRSA was common.
Third, care area (corresponding with level of dependency)
and antimicrobial use were risk factors for carriage of
ESBL-EC and MRSA. Fourth, all ESBL-EC isolates
belonged to the H30-Rx ST131 subclone. Fifth, PFGE di-
vided the H30-Rx subclone into two clusters, one of which
included UK Strain A and a representative of the inter-
national PFGE812 group, the other included UK strain D.
Sixth, all ESBL-EC and ESBL-KP contained blaCTX-M group 1.
Seventh, once subjects acquired ESBL-EC they tended to
remain colonised with the same strain. Eight, we observed
that although ESBL-producing Enterobacteriaceae were
recovered from a much higher proportion of participants
than MRSA, ESBL-producing Enterobacteriaceae was not
detected in the environment, whereas detection of MRSA
was common. Finally, 39% of residents did not become
colonised with ESBL-EC or MRSA at any time, despite
sharing the same LTCF with colonised residents from up
to a year. These findings have significant implications for
our understanding of the relationship between LTCF
and the problem of acquired resistance to antimicrobial
agents.
Several studies have assessed the prevalence of colon-
isation with ESBL-EC among LTCF participants. Our
findings are broadly consistent with those of a previous
study in Northern Ireland. However, our observed col-
onisation prevalence with ESBL-EC (56%) is higher than
that study’s (41%) [20], and is much higher than noted
in previous international LTCF surveillance studies, in-
cluding studies from 2008–2010 and 2003–2012 from
Sweden identified ESBL- EC in just 1/268 (0.004%) and
2/1131 (0.002%) residents respectively. Similarly, studies
performed in 2010 and 2011 from Melbourne identified
ESBL-EC in 14/119 (12%) and 12/115 (10%) of LTCF
residents respectively [41-44].
MRSA colonisation was detected at some time in 27%
of participants, which is similar to a previous study from
Northern Ireland (23% of residents in 45 LTCFs), but
higher than an earlier study performed in six LTCFs in
Ireland between 1995 and 1996 (9% and 10% respect-
ively) [23,45]. It is possible that 27% represents an
underestimate of colonisation, since practical constraints
limited our sampling to nasal swabs. A low prevalence
of MRSA colonisation among LTCF residents was re-
ported from Sweden, the Netherlands, and Denmark
[46-48]. However, these countries have a low proportion
of MRSA bloodstream infections compared with Ireland
[17], which suggests that MRSA is less prevalent overall
as a healthcare-associated organism in those countries
compared with Ireland.
Co-colonisation with ESBL-producing Enterobacteriaceae
and MRSA was common (39%). AlthoughVRE colonisation
was uncommon (3%), it likewise was associated with ESBL-EC and MRSA colonisation. Elsewhere, VRE colonisation
of LTCF residents was not detected in Belgium, but has
been reported in Australia (2%), Israel (10%), and in the
USA (4 to 45%) [42,49-52]. Similarly, Donskey and col-
leagues (2003) found that, in a Department of Veterans Af-
fairs medical centre (which includes an acute care facility
and a separate nursing home), colonisation with MRSA
and ceftazidime-resistant Gram-negative bacilli was more
prevalent among VRE-positive than VRE-negative patients
[53]. Thus our findings of co-colonisation are consistent
with existing literature.
Colonisation with ESBL-producing Enterobacteriaceae
and MRSA were associated with residence in particular
care areas within the LTCF and with antimicrobial con-
sumption. Specifically, participants in care areas 1 and 2
were 3.9 odds more likely to be ESBL colonised, and 6.9
odds more likely to be MRSA colonised. The association
with care area may plausibly reflect the interaction of a
number of factors associated with providing care for the
most dependent residents, including greater resident
vulnerability, and more frequent contact with healthcare
workers. This reflects the challenges of containing
spread of AROs while providing appropriate social, psy-
chological, and physical care for highly dependent resi-
dents in a LTCF.
Participants also had a 2.4-fold higher odds of ESBL col-
onisation and 3.1-fold higher odds of MRSA colonisation
if they received antimicrobial in the three months before
sampling. Fifty-two percent of participants received
antimicrobials during the one-year study period. Broad
spectrum beta-lactam antimicrobials (included amoxi-
cillin, co-amoxiclav, and cefuroxime) were the most
frequently consumed antimicrobials, with amoxicillin-
clavulanic acid accounting for the majority. This is
consistent with the European Surveillance of Antimicro-
bial Consumption point prevalence studies, which identi-
fied beta-lactam antimicrobials and penicillins as the most
common antimicrobials prescribed in Irish LTCFs [54].
The 2013 HALT survey for Ireland reported 9% and
11% respectively as the median overall antimicrobial
use prevalence in general nursing homes (n = 103)
and mixed care facilities (n = 26), both with length-of-
stay > 12 months [55]. Likewise, in 722 European
LTCFs the most commonly prescribed agents were
amoxicillin-clavulanic acid (12.7%), nitrofurantoin (10.4%),
trimethoprim (9.9%), amoxicillin (7.3%), and ciprofloxacin
(6.9%) [24]. A higher point prevalence of antimicrobial
prescribing (16%) has been reported in LTCFs in other
European studies [56,57]. Benoit et al. [58] reported 42%
of residents in 73 LTCFs as receiving antimicrobials in the
previous six months in the USA.
Given that third-generation cephalosporins and fluoro-
quinolones were used infrequently in this facility, it ap-
pears that selective pressure from these agents is not
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onisation with ESBL-producing Enterobacteriaceae or
MRSA. However, we note that in this LTCF the domin-
ant ESBL-Enterobacteriaceae and MRSA are resistant
to broad-spectrum beta-lactams, the most commonly
consumed antimicrobials in the LTCF; thus, the overall
association of colonisation with antimicrobial consump-
tion is not surprising from a microbiological perspective.
It was surprising that nitrofurantoin was independently
associated with ESBL colonisation (OR 3.4 (1.1-11.3)),
since it is generally considered to have limited selective
impact on gut flora [59]. However, record review indicated
that 8/9 participants who received nitrofurantoin prior to
sampling had already been identified as ESBL-positive be-
fore the nitrofurantoin was prescribed, based on clinically-
submitted urine samples. Since nitrofurantoin use in these
patients was most likely guided by prior susceptibility test
reports, and since nitrofurantoin is one of few oral antimi-
crobials active against ESBL-EC, this association can be
explained on that basis.
The finding that all ESBL-EC isolates represented the
ST131 subclone contributes to the evidence that dissemin-
ation of ST131 is a global public health problem in LTCFs.
Banerjee et al. [60] reported that, among consecutive E.
coli clinical isolates from Rochester, Minnesota, ST131
accounted for 80/299 (27%) of isolates from healthcare or
community-associated infections, but for fully 28/37 (76%)
of isolates from LTCFs. Rooney et al. and Dhanji et al.
reported ST131 representing 99% of ESBL-EC collected
from residents of LTCFs in Northern Ireland [20,61]. The
proportion of ST131 we encountered among faecal ESBL-
EC was similar to these reports, and higher than in other
international studies of LTCF residents [20,60,61]. The
predominance of ST131 in LTCFs suggests that such facil-
ities may serve as reservoirs for dissemination of ST131.
This problem is likely to be exacerbated by growing num-
ber of LTCF residents, which currently is approximately
19,800 (2012) in Ireland, 3.7 million in the EU (2010), and
1.5 million in the United States (2009) [24,25,31].
Genomic diversity within ST131 has been described
previously based on sequencing the fimH, gyrA, and
parC genes, PFGE, and whole genome analysis [3,6,7].
The H30 subclone and its H30-Rx subset have been
identified as the major lineages of E. coli associated with
antimicrobial-resistant infections. Colpan et al. [38] found
that the H30 subclone as a whole accounted for ≥ 95% of
fluoroquinolone-resistant and ESBL-producing ST131 iso-
lates from US veterans. Price et al. [7] and Banerjee et al.
[5] reported a high proportion of ESBL-EC as belonging
to the H30-Rx subset; 91% and 92% respectively [5,7].
Similarly, in the present study all ESBL-EC belonged to
the H30-Rx subclone. The H30-Rx subclone has a re-
ported association with sepsis, suggesting that virulence
may be contributing to its epidemiologic success [5,7].Johnson et al. [3] and Colpan et al. [38] identified vari-
ous pulsotypes within ST131, with PFGE968, PFGE800,
and PFGE812 being the most prevalent [3,38]. Here, 91/
98 (93%) of the H30-Rx isolates formed a single PFGE
cluster, at the ≥ 85% similarity level. This group includes
the ST131 UK epidemic strain A and a representative of
international PFGE812 (Figure 1). The latter two refer-
ence strains represent, respectively, the most prevalent
ST131 variant in the UK [40,62] and the most prevalent
European-associated ST131 pulsotype in a large private
PFGE library (unpublished data, J. R. Johnson) [3]. Thus,
the predominance of this clonal group within the study
LTCF is part of the international dissemination of the
H30Rx ST131 subclone. However, six of the remaining
eight H30-Rx isolates, from two participants, formed a
distinct PFGE cluster, Cluster B (Figure 1). It is of inter-
est that this variant was not entirely displaced by the
predominant variant; thus, two variants of the H30-Rx
subclone were circulating in the LTCF.
Our finding of high prevalence of blaCTX-M group 1 is
consistent with a previous reports from Banjeree et al.
[5] and Price et al. [7] demonstrating a high prevalence
(91%) of blaCTX-M-15 within the H30-Rx subclone [5,7].
Additionally, we found that most isolates (87%) also car-
ried blaOXA-1, which was associated with co-amoxiclav
resistance, reflecting inefficient inhibition of OXA enzymes
by clavulanic acid [63]. This finding may be relevant to
the success of this clonal group given the frequent con-
sumption of co-amoxiclav.
Although few, the ESBL-KP in our study were 91%
similar by PFGE (Figure 2). All carried blaCTX-M group 1
and blaOXA-1 and were resistant to co-amoxiclav. The
six ESBL-KP strains were 86% similar to other Irish iso-
lates belonging to K. pneumoniae clonal CC43 (i.e.,
ST48 and ST123) This is consistent with clonal dissem-
ination of ESBL-KP in Ireland, similar to that described
elsewhere [64]. Various clonal groups of K. pneumoniae
have been reported worldwide, such as CC43, which is
commonly associated with resistance enzymes such as
TEM-3, SHV-12, and CTX-M-15 [10,12]. We detected
ESBL-KP for the first time in this LTCF three months
after commencing the study. Given the propensity for
dissemination of such strains of K. pneumoniae [65], it
seems surprising that after nine months of follow-up
only five participants had evidence of colonisation.
The duration of persistence of colonisation with ESBL-
producing Enterobacteriaceae has previously been reported.
The median time to clearance of ESBL-producing En-
terobacteriaceae after hospital discharge was 6.6 months
in a French study [66] and 98 days (i.e., approximately
3 months) in a study from Thailand [67]. A Swedish
study by Titelman et al. [68] concluded that clearance
of ESBL-producing Enterobacteriaceae has not occurred
in many patients (43%) at 12 months after infection and
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carrying blaCTX-M group 9. This study also demonstrated
that failure to detect the organism on sampling does not
reliably establish clearance [68]. However, these studies
did not address residents of LTCFs.
We found that spontaneous clearance of colonisation
of E. coli carrying blaCTX-M group 1 was uncommon; 75%
of ESBL-EC colonised participants who had two or more
subsequent samples after their initial positive swab
remained positive. Moreover, despite the presence within
this LTCF of two different PFGE variants of ESBL-EC
ST131, the variant identified in a given resident was
stable over time. Thus, participants tended to remain
colonised with the same ESBL-EC strain for an extended
period. Furthermore, two initially ESBL-EC-colonised
participants in whom ESBL-EC ST131 was not detected
at 3 or 6 months reverted to being positive at 9 and
12 months, in both cases with isolates that were indistin-
guishable from or ≥ 95% similar to the previous isolates
by PFGE. This is consistent with persistence, or auto-
reinfection. As no environmental contamination with
ESBL-producing Enterobacteriaceae was detected, auto-
reinfection does not appear to be from an environmental
reservoir but more likely from resident-resident interac-
tions or resident-health care worker interactions. This
may also indicate the need for caution in accepting fail-
ure to detect colonisation as confirmation of clearance.
Persistent colonisation was also common for MRSA.
Of the 17 MRSA-colonised participants 73% of those
who had two or more subsequent samples remained
positive. Consistent with standard practice in LTCF in
Ireland this LTCF had no programme of routine resident
MRSA decolonisation.
Regarding environmental contamination, MRSA was
recovered much more commonly from the environment
than was ESBL-EC, despite being recovered from a
smaller proportion of participants, which is consistent
with previous findings [69]. The greater frequency of en-
vironmental detection of MRSA compared with ESBL-E.
coli may reflect more intense shedding of MRSA or bet-
ter environmental survival. The environmental detection
of MRSA compared with no ESBL-EC environmental
contamination may reflect more intense shedding of
MRSA or better environmental survival.
Interestingly, a large number of residents did not be-
come colonised with ESBL-EC or MRSA throughout the
year. This occurred despite an absence of restrictions on
social interactions for residents colonised with MRSA or
ESBL-Enterobacteriaceae, and frequent environmental
contamination with MRSA. It is clear that, as the inverse
of risk factors for colonisation, those who do not become
colonised were less likely to have consumed antimicrobial
agents and to reside in the high-dependency areas.
However, other factors may contribute to colonisationresistance. This phenomenon clearly merits further
study.
The study has several limitations. First, although initial
study enrolment was high and retention was good, both
were incomplete, with represents one of many chal-
lenges in conducting a longitudinal LTCF-based study.
Second, antimicrobial exposure may have been underes-
timated, since antimicrobial use during hospital admis-
sion was not captured. Third, although the observed
clonality of the ESBL-EC and ESBL-KP study isolates
supports dissemination within this LTCF, it is not pos-
sible from the current analysis to differentiate defini-
tively between acquisition of ESBL-producing organisms
within the LTCF vs. during episodes of hospitalisation or
via other exposures. In future studies, emerging higher-
resolution typing methods such as whole-genome se-
quencing could be used to better clarify transmission
pathways [70].
Despite those limitations this study represents a sig-
nificant contribution to research in this area given the
lack of longitudinal studies in LTCFs and there are sev-
eral novel and important findings. Antimicrobial pre-
scribing in LTCFs is an immediately modifiable risk
factor for colonisation with AROs. We demonstrate the
clonality and temporal stability of ESBL-producing
Enterobacteriaceae within a single LTCF. Although
multiple ST131 variants were detected, all belong to
the H30-Rx subclone [5,7]. Colonised participants
tended to retain the same pulsotype over an extended
period. We report the first identified ESBL-KP in an
Irish LTCF. We note that although present in 5 partici-
pants this organism has not disseminated to the same
extent as ESBL-EC (n = 35). Further studies are needed
to clarify the acquisition, retention, and dissemination
of antimicrobial-resistant clones within LTCFs and to
establish if there are other characteristics of such indi-
viduals, e.g., the gut microbiota, that may contribute to
such colonisation resistance.
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